Kyverna Therapeutics (KYTX) filed a registration statement late Thursday for the sale of up to $300 million of securities.
The shelf covers common and preferred stock, debt securities, warrants, rights, units, and depositary shares.
Net proceeds will be used for general corporate purposes, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.